At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase Ib/II, Open-label, Multicenter Study of Novel Oncology Therapies in Combination With Chemotherapy and Bevacizumab as First-line Therapy in Metastatic Microsatellite-stable Colorectal Cancer (COLUMBIA-1)
In Brief
A Phase 2 clinical trial evaluating Durvalumab, Oleclumab, and 2 other interventions for Metastatic Microsatellite-stable Colorectal Cancer. Active but no longer recruiting, targeting 61 participants across 21 sites in 5 countries.
Detailed Summary
COLUMBIA-1 is a Phase 1b/2 platform study to evaluate the safety and efficacy of standard of care (FOLFOX plus bevacizumab) alone and in combination with novel oncology therapies in first-line metastatic microsatellite-stable colorectal cancer (MSS-CRC).
Study Details
Timeline
Interventions
Participants will receive IV infusion of durvalumab as stated in arm description.
Participants will receive IV infusion of oleclumab as stated in arm description.
Participants will receive IV infusion of FOLFOX (5-FU, oxaliplatin, and folinic acid) as stated in arm description.
Participants will receive IV infusion of bevacizumab as stated in arm description.